These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23143775)

  • 1. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V ® and Fluad ® ) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study.
    Gasparini R; Amicizia D; Lai PL; Rossi S; Panatto D
    Hum Vaccin Immunother; 2013 Jan; 9(1):144-52. PubMed ID: 23143775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
    Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D
    Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study.
    Spadea A; Unim B; Colamesta V; Meneghini A; D'Amici AM; Giudiceandrea B; La Torre G
    Vaccine; 2014 Sep; 32(41):5290-4. PubMed ID: 25087677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of influenza vaccine in reducing influenza-associated hospitalizations and deaths among the elderly population; Lazio region, Italy, season 2016-2017.
    Fabiani M; Volpe E; Faraone M; Bella A; Pezzotti P; Chini F
    Expert Rev Vaccines; 2020 May; 19(5):479-489. PubMed ID: 32237925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine.
    Herzog C; Hartmann K; Künzi V; Kürsteiner O; Mischler R; Lazar H; Glück R
    Vaccine; 2009 Jul; 27(33):4381-7. PubMed ID: 19450630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.
    de Bruijn IA; Nauta J; Gerez L; Palache AM
    Vaccine; 2006 Nov; 24(44-46):6629-31. PubMed ID: 16901593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.
    Puig-Barberà J; Diez-Domingo J; Pérez Hoyos S; Belenguer Varea A; González Vidal D
    Vaccine; 2004 Dec; 23(3):283-9. PubMed ID: 15530669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
    Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M
    Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly.
    Lapi F; Marconi E; Simonetti M; Baldo V; Rossi A; Sessa A; Cricelli C
    Expert Rev Vaccines; 2019 Jun; 18(6):663-670. PubMed ID: 31155968
    [No Abstract]   [Full Text] [Related]  

  • 12. Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season.
    Imran M; Puig-Barbera J; Ortiz JR; Lopez-Gonzalez L; Dean A; Bonafede M; Haag MDM
    Influenza Other Respir Viruses; 2024 Apr; 18(4):e13288. PubMed ID: 38644564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 - 2018 season.
    Bella A; Gesualdo F; Orsi A; Arcuri C; Chironna M; Loconsole D; Napoli C; Orsi GB; Manini I; Montomoli E; Alfonsi V; Castrucci MR; Rizzo C
    Expert Rev Vaccines; 2019 Jun; 18(6):671-679. PubMed ID: 31159616
    [No Abstract]   [Full Text] [Related]  

  • 14. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.
    Ansaldi F; Orsi A; de Florentiis D; Parodi V; Rappazzo E; Coppelli M; Durando P; Icardi G
    Hum Vaccin Immunother; 2013 Mar; 9(3):591-8. PubMed ID: 23295262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
    Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J
    Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy.
    Bellino S; Bella A; Puzelli S; Di Martino A; Facchini M; Punzo O; Pezzotti P; Castrucci MR; The InfluNet Study Group
    Expert Rev Vaccines; 2019 Nov; 18(11):1201-1209. PubMed ID: 31674847
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
    Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.
    Salleras L; Domínguez A; Pumarola T; Prat A; Marcos MA; Garrido P; Artigas R; Bau A; Brotons J; Bruna X; Català P; Carreras E; Cuadra D; Gatell A; Millet S; Oller J; Raga E
    Vaccine; 2006 Nov; 24(44-46):6638-42. PubMed ID: 16842892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.